- Home
- JRI vs SGHT Comparison
JRI vs SGHT Comparison
Compare JRI & SGHT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JRI
- SGHT
- Stock Information
- Founded
- JRI 2012
- SGHT 2011
- Country
- JRI United States
- SGHT United States
- Employees
- JRI N/A
- SGHT N/A
- Industry
- JRI Finance Companies
- SGHT Medical Specialities
- Sector
- JRI Finance
- SGHT Health Care
- Exchange
- JRI Nasdaq
- SGHT Nasdaq
- Market Cap
- JRI 337.8M
- SGHT 304.4M
- IPO Year
- JRI N/A
- SGHT 2021
- Fundamental
- Price
- JRI $12.38
- SGHT $2.83
- Analyst Decision
- JRI
- SGHT Buy
- Analyst Count
- JRI 0
- SGHT 7
- Target Price
- JRI N/A
- SGHT $5.10
- AVG Volume (30 Days)
- JRI 68.0K
- SGHT 260.5K
- Earning Date
- JRI 01-01-0001
- SGHT 03-06-2025
- Dividend Yield
- JRI 9.38%
- SGHT N/A
- EPS Growth
- JRI N/A
- SGHT N/A
- EPS
- JRI N/A
- SGHT N/A
- Revenue
- JRI N/A
- SGHT $79,543,000.00
- Revenue This Year
- JRI N/A
- SGHT $2.13
- Revenue Next Year
- JRI N/A
- SGHT $7.99
- P/E Ratio
- JRI N/A
- SGHT N/A
- Revenue Growth
- JRI N/A
- SGHT N/A
- 52 Week Low
- JRI $9.70
- SGHT $2.68
- 52 Week High
- JRI $12.12
- SGHT $8.45
- Technical
- Relative Strength Index (RSI)
- JRI 47.28
- SGHT 22.86
- Support Level
- JRI $12.00
- SGHT $3.46
- Resistance Level
- JRI $12.29
- SGHT $3.34
- Average True Range (ATR)
- JRI 0.18
- SGHT 0.16
- MACD
- JRI 0.05
- SGHT -0.04
- Stochastic Oscillator
- JRI 60.48
- SGHT 14.69
About JRI Nuveen Real Asset Income and Growth Fund of Beneficial Interest
Nuveen Real Asset Income and Growth Fund is the United States-based closed-end fund. Its objective is to provide a high level of current income and long-term capital appreciation. The fund invests a majority of its managed assets in equity and debt securities issued by real asset related companies located anywhere in the world. Its strategy involves investments primarily in five security types, global infrastructure common stock, REIT preferred stock and debt securities. Real asset-related companies include those engaged in owning, operating, or developing infrastructure projects, facilities, and services, as well as REITs.
About SGHT Sight Sciences Inc.
Sight Sciences Inc is an ophthalmic medical device company focused on the development and commercialization of surgical and nonsurgical technologies for the treatment of prevalent eye diseases. Its Surgical Glaucoma segment's product portfolio features the OMNI Surgical System, a device that facilitates the performance of both canaloplasty and trabeculotomy with a single device and single corneal incision to reduce intraocular pressure in adult patients with primary open-angle glaucoma. The company's Dry Eye segment's product portfolio consists of the TearCare System for ophthalmologists and optometrists. It derives key revenue from the Surgical Glaucoma segment.